TWI547484B - 異喹啉化合物,其製備方法及含其之醫藥組合物 - Google Patents

異喹啉化合物,其製備方法及含其之醫藥組合物 Download PDF

Info

Publication number
TWI547484B
TWI547484B TW104105729A TW104105729A TWI547484B TW I547484 B TWI547484 B TW I547484B TW 104105729 A TW104105729 A TW 104105729A TW 104105729 A TW104105729 A TW 104105729A TW I547484 B TWI547484 B TW I547484B
Authority
TW
Taiwan
Prior art keywords
nmr
group
dmso
compound
pharmaceutically acceptable
Prior art date
Application number
TW104105729A
Other languages
English (en)
Chinese (zh)
Other versions
TW201534587A (zh
Inventor
史特法諾 區蒙堤
克莉絲汀 顧雪
艾美 德賽寧
法蘭西斯 居里貝特
貝通 古蒙
馬克 柯奈特
尚 路易 培里昂
克里斯多夫 波特凡
尚 保羅 維連
妮可 維琳奴
Original Assignee
施維雅藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 施維雅藥廠 filed Critical 施維雅藥廠
Publication of TW201534587A publication Critical patent/TW201534587A/zh
Application granted granted Critical
Publication of TWI547484B publication Critical patent/TWI547484B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW104105729A 2014-02-21 2015-02-17 異喹啉化合物,其製備方法及含其之醫藥組合物 TWI547484B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451389A FR3017868A1 (fr) 2014-02-21 2014-02-21 Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
TW201534587A TW201534587A (zh) 2015-09-16
TWI547484B true TWI547484B (zh) 2016-09-01

Family

ID=50424640

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104105729A TWI547484B (zh) 2014-02-21 2015-02-17 異喹啉化合物,其製備方法及含其之醫藥組合物

Country Status (37)

Country Link
US (1) US9809553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3107900B1 (cg-RX-API-DMAC7.html)
JP (1) JP6491226B2 (cg-RX-API-DMAC7.html)
KR (1) KR102251198B1 (cg-RX-API-DMAC7.html)
CN (1) CN105980361B (cg-RX-API-DMAC7.html)
AR (1) AR099493A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015220659B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016017679B1 (cg-RX-API-DMAC7.html)
CA (1) CA2938344C (cg-RX-API-DMAC7.html)
CL (1) CL2016002089A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120034T1 (cg-RX-API-DMAC7.html)
DK (1) DK3107900T3 (cg-RX-API-DMAC7.html)
EA (1) EA030617B1 (cg-RX-API-DMAC7.html)
ES (1) ES2659885T3 (cg-RX-API-DMAC7.html)
FR (1) FR3017868A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20180141T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038337T2 (cg-RX-API-DMAC7.html)
IL (1) IL246721B (cg-RX-API-DMAC7.html)
JO (1) JO3372B1 (cg-RX-API-DMAC7.html)
LT (1) LT3107900T (cg-RX-API-DMAC7.html)
MA (1) MA39207A1 (cg-RX-API-DMAC7.html)
ME (1) ME02863B (cg-RX-API-DMAC7.html)
MX (1) MX363301B (cg-RX-API-DMAC7.html)
MY (1) MY178745A (cg-RX-API-DMAC7.html)
NO (1) NO3107900T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ722513A (cg-RX-API-DMAC7.html)
PL (1) PL3107900T3 (cg-RX-API-DMAC7.html)
PT (1) PT3107900T (cg-RX-API-DMAC7.html)
RS (1) RS56766B1 (cg-RX-API-DMAC7.html)
RU (1) RU2679621C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201605662TA (cg-RX-API-DMAC7.html)
SI (1) SI3107900T1 (cg-RX-API-DMAC7.html)
TW (1) TWI547484B (cg-RX-API-DMAC7.html)
UA (1) UA117953C2 (cg-RX-API-DMAC7.html)
UY (1) UY35997A (cg-RX-API-DMAC7.html)
WO (1) WO2015124877A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201604976B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640496B2 (en) * 2016-06-17 2020-05-05 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
US12338238B2 (en) 2018-06-07 2025-06-24 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP2021529830A (ja) * 2018-07-02 2021-11-04 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) ラクテート増強化合物及びその使用
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
ES2991902T3 (es) 2018-11-06 2024-12-05 Cervello Therapeutics LLC Inhibidores de la cinasa rock
BR112021017354A2 (pt) 2019-03-01 2021-11-16 Beijing Tide Pharmaceutical Co Ltd Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
JP7699820B2 (ja) 2019-03-22 2025-06-30 サニオナ エー/エス 新規カリウムチャネル阻害剤
EP4051680B1 (en) 2019-10-30 2025-09-03 Biogen MA Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
CN115974647B (zh) * 2022-12-05 2024-09-03 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000240A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
WO2008020081A1 (en) * 2006-08-18 2008-02-21 N.V. Organon 6-substituted isoquinoline derivatives as rock-1 inhibitors
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
ATE506967T1 (de) 1999-04-27 2011-05-15 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen
BR0113170A (pt) * 2000-08-11 2004-01-06 Purdue Research Foundation Processo para a preparação de dinapsolina
AU2002326823B2 (en) * 2001-09-06 2005-12-15 Merck Sharp & Dohme Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1470121B1 (en) * 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
MX2008001053A (es) 2005-07-26 2008-03-19 Sanofi Aventis Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa.
PT1912949E (pt) 2005-07-26 2011-11-23 Sanofi Sa Derivados de ciclo-hexilamina isoquinolona como inibidores da rho-cinase
DK2102164T3 (da) 2006-12-27 2011-03-21 Sanofi Aventis Cycloalkylaminsubstituerede isochinolin- og isochinolinonderivater
KR20090094338A (ko) 2006-12-27 2009-09-04 사노피-아벤티스 치환된 이소퀴놀린 및 이소퀴놀리논 유도체
JP5421783B2 (ja) 2006-12-27 2014-02-19 サノフイ Rhoキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
ES2364511T3 (es) 2006-12-27 2011-09-05 Sanofi Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina.
TW200845988A (en) * 2007-04-05 2008-12-01 Astrazeneca Ab New compounds and their uses 707
BRPI0914330A2 (pt) 2008-06-24 2019-09-24 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos bl-e policíclicos
PL2313374T3 (pl) 2008-06-24 2014-03-31 Sanofi Sa 6-podstawione izochinoliny i izochinolinony
US8541449B2 (en) 2008-06-24 2013-09-24 Sanofi Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000240A1 (en) * 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
TWI372756B (en) * 2005-06-28 2012-09-21 Sanofi Aventis Isoquinoline derivatives
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
WO2008020081A1 (en) * 2006-08-18 2008-02-21 N.V. Organon 6-substituted isoquinoline derivatives as rock-1 inhibitors
WO2008077555A2 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors

Also Published As

Publication number Publication date
WO2015124877A1 (fr) 2015-08-27
ME02863B (me) 2018-04-20
SG11201605662TA (en) 2016-08-30
AR099493A1 (es) 2016-07-27
LT3107900T (lt) 2017-12-27
PT3107900T (pt) 2018-01-08
JP2017506251A (ja) 2017-03-02
CY1120034T1 (el) 2018-12-12
RS56766B1 (sr) 2018-04-30
JO3372B1 (ar) 2019-03-13
EP3107900B1 (fr) 2017-11-15
HK1232220A1 (zh) 2018-01-05
AU2015220659A1 (en) 2016-08-04
DK3107900T3 (en) 2018-02-19
MY178745A (en) 2020-10-20
KR102251198B1 (ko) 2021-05-11
CL2016002089A1 (es) 2017-01-27
EP3107900A1 (fr) 2016-12-28
US9809553B2 (en) 2017-11-07
NZ722513A (en) 2019-08-30
ES2659885T3 (es) 2018-03-19
US20170137385A1 (en) 2017-05-18
EA201691675A1 (ru) 2017-02-28
UY35997A (es) 2015-08-31
EA030617B1 (ru) 2018-08-31
FR3017868A1 (fr) 2015-08-28
HRP20180141T1 (hr) 2018-03-09
UA117953C2 (uk) 2018-10-25
PL3107900T3 (pl) 2018-04-30
MA39207A1 (fr) 2017-04-28
ZA201604976B (en) 2022-05-25
RU2679621C2 (ru) 2019-02-12
TW201534587A (zh) 2015-09-16
IL246721B (en) 2018-12-31
KR20160116003A (ko) 2016-10-06
MX2016010779A (es) 2016-10-26
HUE038337T2 (hu) 2018-10-29
SI3107900T1 (en) 2018-02-28
AU2015220659B2 (en) 2018-09-13
MX363301B (es) 2019-03-20
CN105980361A (zh) 2016-09-28
NO3107900T3 (cg-RX-API-DMAC7.html) 2018-04-14
CN105980361B (zh) 2019-05-21
RU2016137502A (ru) 2018-03-27
CA2938344C (fr) 2018-07-03
JP6491226B2 (ja) 2019-03-27
BR112016017679B1 (pt) 2022-07-26
RU2016137502A3 (cg-RX-API-DMAC7.html) 2018-09-24
BR112016017679A2 (cg-RX-API-DMAC7.html) 2017-08-08
CA2938344A1 (fr) 2015-08-27

Similar Documents

Publication Publication Date Title
TWI547484B (zh) 異喹啉化合物,其製備方法及含其之醫藥組合物
TW202204323A (zh) 經取代之嗒𠯤化合物
CN104822267B (zh) 乙型肝炎病毒共价闭合环状dna形成的抑制剂及其使用方法
CN103827101B (zh) 双环二氢喹啉-2-酮衍生物
US6642224B1 (en) Diazepan derivatives or salts thereof
EP3126349B1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
UA55461C2 (uk) 2-амінопіридини, які мають циклоконденсовані замісники, як інгібітори оксиду азоту синтази, фармацевтичні композиції, способи лікування або попередження хворобливих станів та спосіб інгібування оксиду азоту синтази
TW200908961A (en) New pharmaceutical compounds
JP2020515583A (ja) アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
TW200930703A (en) Quinolone derivative
JP2023052610A (ja) タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法
TW201028398A (en) Quinolone compound and pharmaceutical composition
TW201208687A (en) Condensed ring pyridine compound
US20080194584A1 (en) Nitrogen Heteroaromatic Compounds Which Bind To The Active Site Of Protein Kinase Enzymes
JPH06508377A (ja) ヘテロ環式化合物
EP0626373A1 (en) Quinazolinone derivatives
WO2004002484A1 (ja) ホスホジエステラーゼ阻害剤
HUT53867A (en) Process for producing new pyrrolidine derivatives and pharmaceutical compositions comprising such compounds
CN113891879B (zh) 3,6-二取代的-2-吡啶醛肟骨架
TW201002710A (en) Novel (bridged piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
HK1228894B (zh) 用於治疗心血管疾病的5-苄基异喹啉衍生物
HK1228894A1 (en) Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases
JP7026828B2 (ja) 2,3-ジヒドロフロ[2,3-b]ピリジン化合物
EA028215B1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JPH08208595A (ja) スルホンアミド化合物、その製造法および剤